Stock CESSA CESSATECH A/S
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
6.62 DKK +1.85% Intraday chart for Cessatech A/S +5.08% -8.82%
29/02 Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023
Cessatech A/S Appoints Martin Olin as the Chairman of the Board
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022
Cessatech A/S Auditor Raises 'Going Concern' Doubt
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
Cessatech A/S Announces Board Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CESSA Stock
  4. News Cessatech A/S
  5. Other languages